| Name | Title | Contact Details |
|---|
Safety Syringes, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Shield Healthcare offers a dynamic work environment with competitive salaries and a comprehensive benefits package. Check out our careers section for exciting opportunities.
VisionQuest Biomedical Inc. is a research and development company founded in 2007 with the objective of bringing affordable medical devices to the ophthalmic and diabetes care markets. VisionQuest has developed multiple medical devices with funding from the National Institutes of Health and is now looking to transfer those technologies to the commercial space. Our devices are currently being used in the United States and Latin America.
Vital Images is the industry leader in advanced visualization for multi modal imaging in both radiology and cardiology.
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnpod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 100,000 users across the globe rely on Insulet`s Omnipod Insulin Management System to bring simplicity and freedom to their lives. For more information, please visit: www.insulet.com, www.myomnipod.com and https://www.omnipodeurope.com.* *Starting July 1, 2018, Insulet will assume direct distribution of its Omnipod Insulin Management System in Europe, including sales, marketing, training and customer support activities. This will allow Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long term, as it already does in the United States and Canada.